- Email: [email protected]
Correction to Lancet Oncol 2017; 18: 812
Corrections
Correction to Lancet Oncol 2017; 18: 63–74 Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatininduced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18: 63–74—In the Summary and Results of this Article, the sentences regarding adverse events should have read “The most common grade 3–4 haematological adverse events reported, irrespective of attribution, were neutropenia (117 [66%] of 178 participant cycles in the sodium thiosulfate group vs 145 [65%] of 224 in the control group), whereas the most common non-haematological adverse event was hypokalaemia (25 [17%] of 149 vs 22 [12%] of 187)”. In the Results, sentences regarding adverse events should have read “Haematological toxicity was not significantly different between the treatment groups, occurring in 137 (77%) of 178 participant cycles in the sodium thiosulfate group and 172 (77%) of 224 participant cycles in the control group (p=0·97; table 3). Aggregate nephrotoxicity was more common in the sodium thiosulfate group, in which 37 (25%) of 149 participant cycles were affected versus 25 (13%) of 187 controls (p=0·0071; table 4)”; sentences regarding serious adverse events should have read “194 serious adverse events were reported in 26 patients; of these, 127 were deemed unrelated, 47 unlikely, 20 possibly, and none probably or definitely related to sodium thiosulfate. 87 were nonhaematological adverse events, of which 45 were deemed unrelated, 28 unlikely, 14 possibly, and none probably or definitely related to sodium thiosulfate”; sentences regarding median follow-up should have read “Median follow-up was 3·5 years (IQR 3·0–4·5) for event-free www.thelancet.com/oncology Vol 18 June 2017
survival” and “3·5 years (3·0–4·5) for overall survival (median follow-up 3·4 years [2·9–4·3] for the sodium thiosulfate group, and 3·8 years [3·1–4·5] for the control group)”; and sentences regarding localised and disseminated disease should have read “Among participants with localised disease, 14 events in the sodium thiosulfate group, 13 events in the control group, and six deaths in both the control and sodium thiosulfate groups occurred” and “In participants with disseminated disease, 12 events and 11 deaths occurred in the sodium thiosulfate group and 11 events and four deaths occurred in the control group”. Corresponding changes have been made to tables 3 and 4. These corrections have been made to the online version as of June 2, 2017.
Correction to Lancet Oncol 2017; 18: 719–31 Steliarova-Foucher E, Colombet M, Ries LAG, et al, and the IICC-3 contributors. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol 2017; 18: 719–31— In this Article, the coverage of the population of east Asia in table 1 in the “Age 0–14 years” column should have been 4·4%, and in the “Age 15–19 years” column, 4·0%. Consequently, the fourth sentence in the first paragraph of the Results should have read “Approximately 11·4% of the world population aged 0–14 years (contributing 18 376 710 144 person-years) was covered by the registries included in our study, ranging from 1·7% in south Asia (India) to 99·4% in North America (table 1).” These corrections have been made to the online version as of June 2, 2017, and the printed Article is correct.
Correction to Lancet Oncol 2017; 18: 812 Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017; 18: 812–22—In this Article, the affiliation of Umberto Basso should be “Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy”. This correction has been made to the online version as of June 2, 2017, and the printed Article is correct.
e301
Correction to Lancet Oncol 2017; 18: 63–74 Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatininduced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18: 63–74—In the Summary and Results of this Article, the sentences regarding adverse events should have read “The most common grade 3–4 haematological adverse events reported, irrespective of attribution, were neutropenia (117 [66%] of 178 participant cycles in the sodium thiosulfate group vs 145 [65%] of 224 in the control group), whereas the most common non-haematological adverse event was hypokalaemia (25 [17%] of 149 vs 22 [12%] of 187)”. In the Results, sentences regarding adverse events should have read “Haematological toxicity was not significantly different between the treatment groups, occurring in 137 (77%) of 178 participant cycles in the sodium thiosulfate group and 172 (77%) of 224 participant cycles in the control group (p=0·97; table 3). Aggregate nephrotoxicity was more common in the sodium thiosulfate group, in which 37 (25%) of 149 participant cycles were affected versus 25 (13%) of 187 controls (p=0·0071; table 4)”; sentences regarding serious adverse events should have read “194 serious adverse events were reported in 26 patients; of these, 127 were deemed unrelated, 47 unlikely, 20 possibly, and none probably or definitely related to sodium thiosulfate. 87 were nonhaematological adverse events, of which 45 were deemed unrelated, 28 unlikely, 14 possibly, and none probably or definitely related to sodium thiosulfate”; sentences regarding median follow-up should have read “Median follow-up was 3·5 years (IQR 3·0–4·5) for event-free www.thelancet.com/oncology Vol 18 June 2017
survival” and “3·5 years (3·0–4·5) for overall survival (median follow-up 3·4 years [2·9–4·3] for the sodium thiosulfate group, and 3·8 years [3·1–4·5] for the control group)”; and sentences regarding localised and disseminated disease should have read “Among participants with localised disease, 14 events in the sodium thiosulfate group, 13 events in the control group, and six deaths in both the control and sodium thiosulfate groups occurred” and “In participants with disseminated disease, 12 events and 11 deaths occurred in the sodium thiosulfate group and 11 events and four deaths occurred in the control group”. Corresponding changes have been made to tables 3 and 4. These corrections have been made to the online version as of June 2, 2017.
Correction to Lancet Oncol 2017; 18: 719–31 Steliarova-Foucher E, Colombet M, Ries LAG, et al, and the IICC-3 contributors. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol 2017; 18: 719–31— In this Article, the coverage of the population of east Asia in table 1 in the “Age 0–14 years” column should have been 4·4%, and in the “Age 15–19 years” column, 4·0%. Consequently, the fourth sentence in the first paragraph of the Results should have read “Approximately 11·4% of the world population aged 0–14 years (contributing 18 376 710 144 person-years) was covered by the registries included in our study, ranging from 1·7% in south Asia (India) to 99·4% in North America (table 1).” These corrections have been made to the online version as of June 2, 2017, and the printed Article is correct.
Correction to Lancet Oncol 2017; 18: 812 Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017; 18: 812–22—In this Article, the affiliation of Umberto Basso should be “Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy”. This correction has been made to the online version as of June 2, 2017, and the printed Article is correct.
e301